구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Ramucirumab DP |
Overview Company | Eli Lilly and Company |
Overview Modality | ANTIBODY |
Overview Target | Carcinoma of Urinary Tract |
Overview Indication | Carcinoma of Urinary Tract; Urethral Carcinoma |
Overview Phase | PHASE_2 |
Overview Status | ACTIVE |
Overview Content status | Limited Data |
Overview Data Confidence | Data Confidence · Low |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
Toxicology Major finding | FOLFIRI plus ramucirumab versus paclitaxel plus ramucirumab as second-line therapy for patients with advanced or metastatic gastroesophageal adenocarcinoma with or without prior docetaxel - results from the phase II RAMIRIS Study of the German Gastric Cancer Study Group at AIO.. Ramucirumab and paclitaxel is the standard second-line therapy in patients with metastatic gastroesophageal adenocarcino… |
Clinical Safety signal | FOLFIRI plus ramucirumab versus paclitaxel plus ramucirumab as second-line therapy for patients with advanced or metastatic gastroesophageal adenocarcinoma with or without prior docetaxel - results from the phase II RAMIRIS Study of the German Gastric Cancer Study Group at AIO.. Ramucirumab and paclitaxel is the standard second-line therapy in patients with metastatic gastroesophageal adenocarcino… |
Clinical Selected reported efficacy | ORR 28.8% |
Clinical Reported ORR | 28.8% |
Clinical Result source | ClinicalTrials.gov NCT01234402 |
Clinical Program phase | PHASE_2 |
Clinical Trial ref | NCT01234402 |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Ramucirumab DP |
Overview Company | Eli Lilly and Company |
Overview Modality | ANTIBODY |
Overview Target | Carcinoma of Urinary Tract |
Overview Indication | Carcinoma of Urinary Tract; Urethral Carcinoma |
Overview Phase | PHASE_2 |
Overview Status | ACTIVE |
Overview Content status | Limited Data |
Overview Data Confidence | Data Confidence · Low |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
Toxicology Major finding | FOLFIRI plus ramucirumab versus paclitaxel plus ramucirumab as second-line therapy for patients with advanced or metastatic gastroesophageal adenocarcinoma with or without prior docetaxel - results from the phase II RAMIRIS Study of the German Gastric Cancer Study Group at AIO.. Ramucirumab and paclitaxel is the standard second-line therapy in patients with metastatic gastroesophageal adenocarcino… |
Clinical Safety signal | FOLFIRI plus ramucirumab versus paclitaxel plus ramucirumab as second-line therapy for patients with advanced or metastatic gastroesophageal adenocarcinoma with or without prior docetaxel - results from the phase II RAMIRIS Study of the German Gastric Cancer Study Group at AIO.. Ramucirumab and paclitaxel is the standard second-line therapy in patients with metastatic gastroesophageal adenocarcino… |
Clinical Selected reported efficacy | ORR 28.8% |
Clinical Reported ORR | 28.8% |
Clinical Result source | ClinicalTrials.gov NCT01234402 |
Clinical Program phase | PHASE_2 |
Clinical Trial ref | NCT01234402 |
추천 비교
추천 비교